On November 6, Apichope Pharmaceutical(300723.SZ) announced that recently, its controlling subsidiary Guangdong Huazhou Biotech Co., Ltd. (referred to as "Huazhou Biotech" below) independently developed a quadrivalent influenza recombinant protein vaccine. The application for clinical trials of this drug has been approved by the National Medical Products Administration, and received the "Notice of Approval for Drug Clinical Trials" (Notice No.: 2024LP02496), allowing clinical trials for the prevention of influenza.
The quadrivalent influenza recombinant protein vaccine that obtained the clinical trial application this time can stimulate the body to produce immunity against four types of influenza viruses, used to prevent seasonal influenza caused by infection of type A and type B influenza viruses in individuals aged 18 and above.
